Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 503 clinical trials
Efficacy Study of Deep Brain Stimulation in Patients With Treatment Resistant Major Depression

Stimulation (DBS) in patients with treatment resistant major depression using the Boston Scientific implantable Vercise GEVIA DBS system compared to sham.

  • 26 Jan, 2021
  • 2 locations
CLE-100 as an Oral Therapy in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study

The clinical trial is a Phase 2, double-blind, randomized, placebo controlled study in Major Depressive Disorder (MDD) participants currently treated with antidepressant therapy. The objective

  • 07 Sep, 2021
  • 27 locations
A Diagnosis and Treatment Optimization Study of Depression Based on the Neurological Mechanism of Reward System

Major depressive disorder (MDD) is a high-disabling disease. But its etiology and pathogenesis is not clear, and early recognition, diagnosis and treatment still has many challenges. Among

  • 23 Jan, 2021
  • 1 location
Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent

Study of efficacy and safety of MIJ821 in addition to comprehensive standard of care on the rapid reduction of symptoms of Major Depressive Disorder (MDD) in subjects who have suicidal ideation

  • 23 Aug, 2021
  • 6 locations
A Study in Healthy Japanese Men to Test How Well Different Doses of BI 1569912 Are Tolerated

basis for a clinical development of BI 1569912 in the indication for Major Depressive Disorder (MDD) in Japan.

  • 15 Sep, 2021
  • 1 location
Treating Depressed Mood With a Smartphone-delivered Positive Word Stimulation for Subthreshold Depression

Major depressive disorder (MDD) is an important public health problem. Thus, preventive interventions against subthreshold depression (StD), which is one of the key risk factors for the

  • 10 Mar, 2021
  • 1 location
Examining Reward-Related Predictors and Mechanisms of Change in BA Treatment for Anhedonic Adolescents

The prevalence of major depressive disorder (MDD) is relatively low in childhood (i.e., 1-3%), but increases substantially during adolescence. By the age of 18, approximately 15% of adolescents

  • 15 Sep, 2021
  • 1 location
Psilocybin in Depression Resistant to Standard Treatments

treatment resistant major depressive disorder. The primary objective is to evaluate feasibility by measuring recruitment rates, dropout rates and by estimating the variance of the primary outcome measure

  • 30 Jul, 2021
  • 1 location
Definitive Selection of Neuroimaging Biomarkers for the Diagnosis and Treatment to Common Mental Disorders

To explore the whole-brain anatomical and functional abnormalities in drug-naive patients with schizophrenia ,drug-naive patients with BD, drug-naive patients with MDD and healthy controls by

  • 25 Jan, 2021
  • 1 location
Acute Effects of a Standardized Saffron Extract and Its Main Volatile Compound on Stress Response in Healthy Adults

cardiovascular, neuroendocrine and central nervous systems. Moreover, it is well established that stress is the most common risk factor for the development of mood and anxiety disorders, such as major depressive

  • 27 Jan, 2021
  • 1 location